Press Release: CBSET’s CEO Peter Markham honored as ‘2019 Biomedical Research Business Leader’ by Massachusetts Society for Medical Research (MSMR)

PeterMarkham-picLEXINGTON, MA, Oct. 24, 2019 — CBSET Inc., a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, announced today that its co-founder, president and chief executive officer, Peter Markham, has been named ‘2019 Biomedical Research Business Leader’ by the Massachusetts Society for Medical Research (MSMR). He will be honored at a special MSMR event Friday, Oct. 25th, 2019, at The Union Club in downtown Boston.

Since 1953, MSMR has honored select individuals for their contributions to biomedical research. Previous Business Leader honorees have included Robert Coughlin, Massachusetts Biotechnology Council; Dr. Michael Ehlers, Biogen; Dr. Mark Fishman, Novartis Institute for Biomedical Research; James Foster, Charles River Laboratories; Mark Levin, Third Rock Ventures; Dr. John Maraganore, Alnylam Pharmaceuticals; Terry McGuire, Polaris Ventures; Lita Nelsen, MIT; and Henri Termeer, Genzyme.

“Peter is most deserving of this appreciation,” said Elazer R. Edelman, M.D., Ph.D., Director of MIT’s Institute of Medical Engineering, and Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology as well as attending cardiologist at Brigham and Women’s Hospital. “For the past 13 years he has led CBSET to advance biomedical research by accelerating the evolution of technical and scientific acumen through collaborative projects in the medical device, pharmaceutical and academic communities,” added Dr. Edelman, who also is chairman and co-founder of CBSET, and a previous Investigator MSMR honoree (2018).

Prior to co-founding CBSET in 2006, Mr. Markham served as General Manager of the Worcester/Southbridge division of Charles River Laboratories where he had P&L responsibility for a multi-disciplinary preclinical business unit which serviced the Toxicology, Pharmacology, Surgery, Metabolism, Pharmacokinetics, and Bioanalytical Chemistry markets. Prior to CRL, he served as a senior executive at various scientific research companies including: Genzyme Transgenics, Primedica Corporation, BioDevelopment Laboratories, and Arthur D. Little, where he played key roles in corporate acquisitions and created several novel business units through strategic implementation of newly marketed technologies.


CBSET Inc. — 500 Shire Way, Lexington, MA 02421 — is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products. Learn more about CBSET’s expert biomedical research services or please contact us.